ClinicalTrials.gg
CompletedNCT02616640Updated Sep 19, 2024

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

A Phase 1 interventional study of Durvalumab and Pomalidomide in Multiple Myeloma, sponsored by Celgene. Completed at 22 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 149 studies in Multiple Myeloma by Bristol-Myers Squibb — 9 open to participants now, 18 under way, 6 of them phase 3. Multiple Myeloma · Bristol-Myers Squibb.

Enrollment
47th of 108
114 · median 83
Started
2016
with 12 others
Phase 1
40 of 149
2 open now
Registered
85th of 149
by date

Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 47th largest by enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2016, is one of 40 in phase 1, and was the 85th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

9 of the 149 studies in Multiple Myeloma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Multiple Myeloma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase 1b study to determine the recommended dose and regimen of durvalumab either as monotherapy or in combination with POM with or without low dose dex in subjects with RRMM. The study will consist of a dose-finding portion as well as a parallel dose-expansion portion to determine the optimal dose and regimen.

On 05 Sep 2017, a Partial Clinical Hold was placed on this study by the United States (US) Food and Drug Administration (FDA). The decision by the FDA was based on data related to risks of anti-programmed cell death-1 (PD-1) antibody, pembrolizumab, in combination with IMiDs® immunomodulatory drugs in patients with multiple myeloma. As a result, enrollment into this study has been discontinued. Subjects who are receiving clinical benefit, based on the discretion of the investigator, may remain on study treatment after being reconsented.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • Relapsed
  • Refractory
  • MEDI4736
  • Durvalumab
  • Pomalidomide (POM)
  • Dexamethasone (DEX)
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed diagnosis of active multiple myeloma and .
  • Must have undergone prior treatment with ≥2 treatment lines of anti-myeloma therapy
  • Must have failed last ( to last line of treatment).
  • Must have achieved at least a stable disease (SD) for at least 1 cycle of treatment to at least 1 prior anti-myeloma regimen before developing Progressive disease (PD) (relapsed)
  • Prior anti-myeloma treatments must have included a lenalidomide AND proteasome inhibitor alone or in combination.
  • Has performance status of 0, 1, or 2 on the (ECOG) Performance Scale.
  • The extramedullary plasmacytoma (EMP) sub-group, must have radiologically measurable EMP disease (soft tissue or bone related) that is amenable to and does not need to have measurable disease.

Exclusion criteria

Exclusion Criteria:

  • Has non-secretory or oligosecretory multiple myeloma
  • Has had prior anti-myeloma therapy within 2 weeks prior to study Day 1
  • Has undergone prior organ or allogeneic hematopoetic stem cell transplantation
  • Has received previous therapy with pomalidomide and did not achieve at least a stable disease
  • Has received prior therapy with an anti-programmed cell death 1 receptor (), antiprogrammed death-ligand 1 (anti-PD-L1), antiprogrammed death-ligand 2 (anti-PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).
  • Has received prior treatment with a monoclonal antibody within 5 half-lives of Study Day 1
  • Has received agents within 28 days or 5 half-lives (whichever is longer) of Study Day 1
  • Has received live, attenuated vaccine within 30 days prior to Study Day 1
  • Had rash ≥ Grade 3 during prior thalidomide, lenalidomide, or pomalidomide therapy
  • Has a history of anaphylaxis or to thalidomide, lenalidomide, POM, or dex
  • Has peripheral neuropathy ≥ Grade 2
  • Has a known additional that is progressing or requires active treatment (except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy).
  • Is positive for (HIV), chronic or active or active hepatitis A or C
  • Has a prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years (with the exception Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histologic finding of prostate cancer [T1a or T1b] or prostate cancer that is curative)
  • Has clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS multiple myeloma
  • Has cardiac disease
  • Is a female who is pregnant, nursing, or breastfeeding, or who intends to become pregnant during the participation in the study
  • Is a current smoker
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Durvalumab monotherapy

    Intravenous (IV) durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle

    Drug: Durvalumab

  • Experimental
    Durvalumab + pomalidomide (POM)

    IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle and Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle

    Drug: Durvalumab · Drug: Pomalidomide

  • Experimental
    Durvalumab + pomalidomide (POM) + dexamethasone (dex)

    IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle with Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle and Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle

    Drug: Durvalumab · Drug: Pomalidomide · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicities (DLTs)

    Number of participants with DLTs in the first cycle of treatment

    Time frame: Approximately 1 month

Secondary outcomes

  1. Adverse Events (AEs)

    Number of participants with adverse events

    Time frame: Up to approximately 2 year

  2. Overall response rate (ORR)

    Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria

    Time frame: Up to approximately 2 year

  3. Time to response (TTR)

    Time from first dose to the first documentation of response (Partial Response \[PR\] or greater)

    Time frame: Up to approximately 2 year

  4. Duration of response (DOR)

    Is defined as time from the earliest date of documented response (partial response (PR) or better) to the earliest date when disease progression was confirmed

    Time frame: Up to approximately 2 year

  5. Pharmacokinetics- Cmax

    Maximum observed concentration

    Time frame: Up to approximately 1 year

  6. Pharmacokinetics- AUC

    Area under the concentration-time curve

    Time frame: Up to approximately 1 year

  7. Pharmacokinetics- Tmax

    Time to maximum concentration

    Time frame: Up to approximately 1 year

  8. Pharmacokinetics- t1/2

    Terminal elimination half-life

    Time frame: Up to approximately 1 year

  9. Pharmacokinetics- CL/F

    Apparent total body clearance

    Time frame: Up to approximately 1 year

  10. Pharmacokinetics- Vz/F

    Volume of distribution

    Time frame: Up to approximately 1 year

07

Study locations

22 sites
  • Local Institution - 102
    Baltimore, Maryland 21231, United States
  • Local Institution - 114
    Boston, Massachusetts 02114, United States
  • Local Institution - 108
    Boston, Massachusetts 02115, United States
  • Local Institution - 115
    Boston, Massachusetts 02215, United States
  • Local Institution - 105
    New York, New York 10065, United States
  • Local Institution - 106
    Charlotte, North Carolina 28204, United States
  • Local Institution - 110
    Cleveland, Ohio 44195, United States
  • Local Institution - 107
    Milwaukee, Wisconsin 53226, United States
  • Local Institution - 201
    Calgary, Alberta T2N 4N2, Canada
  • Local Institution - 601
    Lille, 59037, France
  • Local Institution - 602
    Poitiers Cedex, 86021, France
  • Local Institution - 603
    Toulouse CEDEX 9, 31059, France
  • Local Institution - 301
    Tuebingen, 72076, Germany
  • Local Institution - 403
    Pavia 2, 27100, Italy
  • Local Institution - 405
    Rozzano (MI), 20089, Italy
  • Local Institution - 401
    Torino, 10126, Italy
  • Local Institution - 702
    Amsterdam, 1081 HV, Netherlands
  • Local Institution - 701
    Rotterdam, 3015 CN, Netherlands
  • Local Institution - 501
    Barcelona, 08916, Spain
  • Local Institution - 504
    Madrid, 28041, Spain
  • Local Institution - 502
    Pamplona, 31008, Spain
  • Local Institution - 505
    Valencia, 46026, Spain
08

References and documents

Publications

  • Young MH, Pietz G, Whalen E, Copeland W, Thompson E, Fox BA, Newhall KJ. Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. Sci Rep. 2021 Aug 12;11(1):16460. doi: 10.1038/s41598-021-95902-x. PubMed 34385543 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Nov 2018, 34 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 34 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2015
First posted
Nov 30, 2015
StartActual
Jan 11, 2016
Primary completionActual
Nov 23, 2018
CompletionActual
Jul 30, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02616640
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 30, 2015
Start date
Jan 11, 2016
Primary completion
Nov 23, 2018
Completion
Jul 30, 2024
Last update
Sep 19, 2024

Study contacts

Lars Sternas, MD, PhD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion